Book Value per Share: Calidi Bio (CLDI)

Public company logo of Calidi Biotherapeutics (CLDI)

Leveraging a science-intensive approach and the expertise of cell biologists, Calidi Biotherapeutics (CLDI) is developing innovative therapies. The change in BVPS reflects the dynamics of net assets, where the 1.49 mark characterizes this parameter. Future prospects depend on clinical trial results and the inflow of investment. Shareholder confidence is supported by stable management establishing partnerships with global medical centers.

Calidi Bio (CLDI) - Accounting Value per Share from 02/21/2024 to 10/27/2026

Summary analytical data breakdowns for Calidi Biotherapeutics Inc. (CLDI)

- price and consensus price forecast:
Stock Price Calidi Bio|CLDI - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Calidi Biotherapeutics, Inc.|CLDI - Company Buyout Price
- book capitalization data:
Book Value per Share Calidi Biotherapeutics|CLDI - Company Net Assets|Market Capitalization to Book Value Ratio calidibio.com|CLDI - Company Total Assets
- debt and liquidity data:
Debt to Equity Calidi Biotherapeutics|CLDI - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Calidi Bio|CLDI - Company Total Debt|Debts to Book Capitalization Calidi Biotherapeutics, Inc.
Analysis of all company metrics:calidibio.com, CLDI
Manufactured product of Calidi Biotherapeutics Inc.

From a portfolio management perspective, this indicator determines the portion of equity attributable to a single share after deducting all liabilities, serving as a measure of the business's intrinsic value. By analyzing the absolute level of the book value per share, an investor assesses the financial cushion of Calidi Biotherapeutics (CLDI) for developing its unique stem cell-based virus delivery technology, thereby determining the company's resilience to clinical trial costs.

Competitor analysis for Calidi Biotherapeutics

BeiGene Corp (ONC) - Book Value per Share|HALO - Equity per Share|Revolution Medicines - Book Value per Share|ascentage.com (AAPG) - Net Assets per Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|Aadi Bio - Accounting Value per Share|TCRX: Book Value per Share|Net Assets per Single Share championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of a Share|Book Value per Share CVM (CEL-SCI Corp.)|Net Asset Value per Share OS Therapies, Inc.|Book Value per Share RADX (Radiopharm Theranostics Limited)|Accounting Value per Share artivabio.com (ARTV)|Book Value per Share ANL (Adlai Nortye)|Veru Inc - Book Value per Share|TPST - Net Assets per Single Share|XLO - Net Assets per Single Share|renovarobio.com - Book Value per Share|Mural Oncology (MURA) - Net Assets per Share|Book Value per Share Kairos Pharma Limited (KAPA)|Equity per Share OnKure|GDTC (CytoMed Therapeutics) - Book Value per Share|Net Assets per Share curis.com CRIS|Accounting Value per Share Apollomics|Accounting Value of a Share tharimmune.com THAR|ADVB - Book Value per Share|GNPX - Net Assets per Single Share|Sunshine Biopharma, Inc. - Book Value per Share|XBIO (Xenetic Biosciences, Inc.) - Net Assets per Share|Net Assets per Single Share SLRX (Salarius Pharmaceuticals)|Net Asset Value per Share purple-biotech.com (PPBT)|Accounting Value per Share American Oncology Network|Book Price of a Share BeiGene Ltd. (BGNE)|Book Value per Share Checkpoint Therapeutics, Inc|Accounting Value of a Share elevationoncology.com ELEV|ICAD (iCAD Corp) - Book Value per Share|IKNA: Net Asset Value per Share|Net Assets per Single Share Notable Labs NTBL|Viracta Therapeutics, Inc. (VIRX) - Accounting Value of a Share|MOR (MorphoSys Corp) - Book Value per Share|Book Value per Share NAYA|AAPGV - Net Assets per Single Share